论文部分内容阅读
目的 分析神经鞘瘤 2 2号染色体 (CHR2 2 )杂合子丢失及其与临床行为之间的关系。方法 选择 4个具有高度多态性的微卫星标记物 ,通过变性聚丙烯酰胺凝胶、银染观察 3 6例神经鞘瘤CHR2 2杂合子丢失 (LOH)频率 ;以免疫组织化学方法检测Ki 67、PCNA的增殖指数。结果 3 6例神经鞘瘤中 15例发生CHR2 2杂合子丢失 (41.6% ) ,4个微卫星标记物缺失的频率分别为 19.4% (D2 2S2 68)、2 2 .2 % (D2 2S2 64 )、19.4% (D2 2S2 80 )、16.7% (CRYB2 ) ;发生CHR2 2缺失的神经鞘瘤的增殖指数高于无缺失者 (P <0 .0 5 )。结论 CHR2 2杂合子丢失是神经鞘瘤发生中的常发事件 ,缺失的区域包括NF2基因 ,CHR2 2杂合子丢失与听神经瘤的临床行为有一定的关系 ,CHR2 2杂合子丢失可能是神经鞘瘤增殖的重要因素
Objective To analyze the loss of heterozygote of schwannoma chromosome 2 (CHR2 2) and its relationship with clinical behavior. Methods Four microsatellite markers with high degree of polymorphism were selected and the frequencies of heterozygous CHL2 2 loss in 36 Schwannoma tumors were observed by silver staining and denatured polyacrylamide gel. The Ki 67 , PCNA proliferation index. Results The loss of CHR2 2 heterozygotes (41.6%) occurred in 15 of 36 schwannomas. The frequency of deletion of 4 microsatellite markers was 19.4% (D2 2S2 68), 22.2% (D2 2S2 64) , 19.4% (D2 2S280) and 16.7% (CRYB2). The proliferation index of schwannomas with CHR2 2 deletion was higher than that without deletion (P <0.05). Conclusion The loss of CHR2 2 heterozygote is a frequent event in Schwannoma. The loss of CHR2 2 heterozygote is related to the clinical behavior of acoustic neuroma. The loss of CHR2 2 heterozygote may be the result of schwannoma An important factor in proliferation